AbbVie Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? AbbVie Inc trades at $249.53 (market cap $438.19B), while VanEck Rare Earth/Strategic Metals trades at $77.5. The key difference: AbbVie Inc pays a 2.79% dividend while VanEck Rare Earth/Strategic Metals pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| ABBV | REMX | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $109.53 |
52-Week Low | $197.38 | $56.60 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.04, up 4.93% in the past 24 hours, reflecting strong momentum amid bullish technical signals. The ETF's high volatility (~50% annualized) and exposure to rare earth metals, critical for technology and defense, align with recent U.S. policy shifts to secure supply chains. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Support levels are clustered near $76-$77, with resistance at $78-$79, indicating a tight trading range.
Outlook hinges on geopolitical trends favoring rare earth independence from China, but risks include extreme volatility and China-dominated holdings. Analyst sentiment is mixed, with technical indicators suggesting near-term strength but overbought conditions. Investors should weigh the ETF's strategic theme against its suitability for conservative portfolios.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →